Abstract: The present invention relates to a composition including, as active substance, a mixture of at least one polyunsaturated fatty acid, different from polyunsaturated fatty acid derived from milk, polyphenols, milk proteins and lactic bacteria, and the composition having a water content of at least 50% by weight; and wherein the polyunsaturated fatty acid presents an increased bioavailability compared with the one of the polyunsaturated fatty acid alone.

Abstract: The present invention relates to methods for a long-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and ?-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-glucoside.

Abstract: The present invention provides a method for the treatment or prevention of an allergic airways disease in a subject, the method comprising administering to the subject a composition comprising Streptococcus pneumoniae or one or more antigens derived therefrom. Also provided are methods and compositions for inducing protective immunity against an allergic airways disease, suppressing an allergic immune response, and treating or preventing conditions such as eosinophilia, mucous secreting cell expression, airway hyperresponsiveness and Th2-mediated disease.

Abstract: The present invention provides a composition and fermented milk, which is derived from natural product, is highly safe, exhibits improvement effect and/or therapeutic effect on skin, and comprises fermented lactic acid bacteria excellent in manufacturability. Disclosed are: use of Streptococcus thermophilus OLS3059 in skin improvement and/or treatment; a composition for skin improvement and/or treatment comprising Streptococcus thermophilus OLS3059 and/or a culture thereof; food and drink comprising the composition; fermented milk for skin improvement and/or treatment prepared by using Lactobacillus delbrueckii subspecies bulgaricus and Streptococcus thermophilus OLS3059; and the fermented milk for skin improvement and/or treatment further comprising collagen peptide and/or ceramide.

Abstract: A dietary supplement composition having an ORAC value in excess of at least about 2,500 and which can be readily consumed in a small quantity is provided for supplementing an individual's daily intake. The dietary supplement composition suitably includes organic and/or vegan ingredients and can be consumed in quantities of as little as about 1 tablespoon to provide an amount of antioxidants equivalent to at least the minimum recommended daily intake of five to nine servings of fruits and/or vegetables.

Abstract: The present invention discloses an oral composition comprising a combination of probiotic bacteria selected from the group comprising Streptococcus, Eubacterium, Neisseria, Veillonella and pH-rising and/or buffering components, which re-establishes an oral microflora associated with good oral health in subjects with a disturbed oral microflora. The invention also discloses the use of the oral composition in combination with other oral health promoting products to help subjects suffering from disorders such as oral dryness, caries, halitosis, inflamed oral mucous membranes or oral fungal infections to restore good oral health.

Abstract: The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 102 and 105 cfu/g of dry formula. The invention further extends to the use of such an infant formula to modulate the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed babies as well as to promote the maturation of the immune system of a neonatal infant in the first few weeks of life.

Abstract: Describes a new strain of Streptococcus thermophilus ssp. salivarius (deposited on 4 Dec. 2001 at the DSMZ—Deutsche Sammlung von Mikroorganismen und Zeilkulturen GmbH, Braunschweig, Germany, with accession No. DSM 14667) and edible compositions, drugs and veterinary products containing it. The use of the said strain is particularly effective in the prevention/treatment of hepatic steatosis (fatty liver) and in nonalcoholic hepatic steatosis.

Abstract: Peptides derived from S. pneumoniae are identified as virulence determinants and may be useful in the preparation of vaccines for the treatment of infection. The peptides may be used as antigens or in the preparation of attenuated microorganisms for use as live oral vaccines.

Abstract: An exemplary embodiment providing one or more improvements includes probiotic compositions comprising probiotic microorganisms with dried vegetable, fruit, cereal, or herb powder. Feeding human or animals either having biological or environmental changes with probiotic compositions has a positive effect in relieving the changes. Positive effects has been demonstrated in humans, dogs, and fish.

Abstract: The invention relates to porous films comprising crosslinked electrospun hydrogel fibers. Viable microbes are encapsulated within the crosslinked electrospun hydrogel fibers. The crosslinked electrospun hydrogel fibers are water insoluble and permeable. The invention also relates to methods of making and using such porous films.

Abstract: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicle for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention.

Abstract: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.

Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the prevention al and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.

Abstract: Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. Also included are methods of treating a respiratory condition, preferably by enhancing immune response, in a mammal. Kits containing the compositions, and instructions for applying the methods are also included. The method includes orally administering to the mammal a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component.

Abstract: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS.

Abstract: Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar alcohols mannitol, sorbitol, and lactitol, and/or phytonutrients such as oligomeric proanthocyanidins (OPCs). The probiotic compositions may be formulated into oral dosage forms such as tablets, caplets, and capsules, or manufactured as a chewing gum or as a powder formulation that may be dissolved in a liquid such as water, milk, juice, or yogurt.

Abstract: The aim of the present invention is a method for the preparation of anallergic probiotic bacterial cultures.

Abstract: Disclosed are methods of increasing the virulence of a bacteriophage, comprising contacting a bacteriophage with a composition comprising a bacterium or bacterial extract; and a polymer. Also disclosed are methods of propagating and isolating therapeutic bacteriophages that involve use of dilute polymer compositions. Also disclosed are pharmaceutical compositions the bacteriophage for which virulence has been increased by the methods set forth herein or which have been isolated by the methods set forth herein.

Abstract: The cosmetic use of at least an effective amount of hesperidin or of one of its derivatives in combination with at least an effective amount of at least one microorganism, in particular probiotic microorganism, or one of its fractions as agent for preventing a reduction in and/or for reinforcing the barrier function of the skin.

Abstract: The present invention relates to a composition which is in the form of a water-soluble anhydrous film comprising at least one water-soluble or water-dispersible film-forming polymer, and at least one live, in particular probiotic, microorganism. It also relates to a kit containing such a composition, as a combination with a secondary composition.

Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Abstract: The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

Abstract: The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.

Abstract: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.

Abstract: This document provide materials and methods for treating patients infected with a spore-forming bacteria and materials and methods for preventing development of Clostridium difficile-associated disease.

Abstract: The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa.

Abstract: The invention relates to an S thermophilus bacterium which is resistant to attack by at least one bacteriophage, a method of production of the bacterium and a composition which comprises the bacterium. The bacterium comprises a modification of the Sfi21 prophage or the bacterial genome which disrupts expression of a gene which is essential to a bacteriophage, but not essential to the bacteria.

Abstract: Composition containing a conditioned cell culture medium or an extract thereof, said medium being able to be obtained by contact with at least one culture of digestive tract cells and at least one probiotic microorganism. It also relates to the use of conditioned culture medium for improving skin homeostasis, etc.

Abstract: A formulation for promoting sinus health includes at least one probiotic agent in combination with N-acetyl cysteine (NAC) and a bioflavonoid or derivative thereof.

Abstract: This invention relates to the treatment of atherosclerotic conditions through the inhibition of lipid oxidising abzymes by altering the composition of the intestinal microbial flora, for example by administering a bacterial composition to the individual. Suitable bacterial compositions may comprise, for example enteric bacteria such as lactobacilli spp, bifidobacteria spp, streptococcal spp and E. coli.

Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.

Abstract: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.

Abstract: A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of viral infections and the diseases associated with such viral infections. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made compositions comprising a substance exhibiting Tubercin and/or SSM activity or a functional derivative thereof.

Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.

Abstract: A reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein. The substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix. Upon reaction between the streptococcus enzymatically activate protein and the substrate, a color change discernable by an unaided human eye results. Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.

Abstract: The disclosed device relates to an animal nutritional supplement and more particularly to a method of using an animal nutritional supplement to reduce the incidence and effects of one or more chronic or acute conditions associated with nutritional deficiencies, gastrointestinal sand accumulation, colitis, inflammatory bowel disease, bacterial colitis, gastrointestinal pH irregularities, colonic ulcers, colonic motility deficiencies, colic, gastrointestinal fermentation deficiencies, pathological changes of certain organs in equine, and possibly even physical aging. One embodiment of the animal nutritional supplement comprises psyllium in combination with a blend of synbiotics.

Abstract: This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.

Abstract: Describes a new strain of Streptococcus thermophilus ssp. salivarius (deposited on 4 Dec. 2001 at the DSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany, with accession No. DSM 14667) and edible compositions, drugs and veterinary products containing it. The use of the said strain is particularly effective in the prevention/treatment of hepatic steatosis (fatty liver) and in nonalcoholic hepatic steatosis.

Abstract: A composition prepared from intact killed cells of isolated ?-hemolytic Streptococcus agalactiae and a concentrated extract of a culture of ?-hemolytic Streptococcus agalactiae, is effective for the protection of fish against infection by the same and other virulent strains Streptococcus agalactiae.

Abstract: The present invention relates to vaccine composition(s) comprising at least two PspAs from strains selected from at least one family, the family being defined by PspAs from strains belonging to the family having greater than or equal to 50% homology in aligned sequences of a C-terminal region of an alpha helical region of PspA. Additionally, the families are further comprised of clades, wherein PspAs from strains which belong to a clade exhibit greater than 75% sequence homology in aligned sequences of the C-terminal region of the alpha helix of PspA. Vaccine compositions of the present invention preferably comprise a minimum of 4 and a maximum of 6 strains representing a single clade each, and the at least two PspAs are optionally serologically or broadly cross-reactive.

Abstract: Particles containing dehydrated living micro-organisms are coated with a homogeneous layer of hydrophobic substance selected to reduce the risks of degradation of the micro-organisms by physico-chemical stresses such as heat, humidity, gastric acid, or compression. A method for producing such particles includes injecting a melting hydrophobic substance into the mass of the dehydrated micro-organisms placed in a chamber swept by an air stream at controlled temperature, where the base is rotating.

Abstract: The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.

Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.

Abstract: A method of producing a hydrolyzed fermented medium containing microorganisms includes providing at least one solid plant product reduced to small pieces and mixed with sugar and biocompatible liquid such as milk for fermentation at a temperature of between 35 and 58 degrees C. until the acidity of the medium reaches the range of 300 to 900 in Terner degrees. Alternatively, the medium is prepared by mixing in predetermined amounts of sprouted grains, biocompatible liquid inoculated with at least one of a variety of non-pathogenic microorganisms, vegetables, fruits, berries, high protein products, herbs, sugar, and a chemical element such as potassium. The mixture is then fermented at a selected temperature for a specified length of time to reach high acidity and high concentration of products of bacterial metabolism. A liquid phase is separated from a solid sediment phase and can be used to treat a wide variety of diseases.

Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.

Abstract: This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.

Abstract: Enteral compositions containing Streptococcus thermophilus, Bifidobacterium infantis and Bifidobacterium longum, each at a concentration equal to or greater than 1×1011 CFU per gram, are useful as adjuncts for enteral formulations and as oral nutritional supplements. The compositions can be administered before, during or at the end of an enteral formulation administration. The compositions can be administered separately or mixed with the enteral formulation. The compositions can also be employed at the end of the daily administration in order to prevent the colonization of the enteral tube by the other pathogens. The compositions can also be used as supplement to any liquid, creamy or pasty foodstuff. The present invention relates to a kit comprising two containers, one containing a foodstuff and the other containing the enteral composition consisting of Streptococcus thermophilus, Bifidobacterium infantis and Bifidobacterium longum.

Abstract: A pharmaceutical composition containing several different bacteria including Streptococcus thermophilus, Lactobacilli and Bifidobacteria is disclosed. The bacteria are present in the composition at a total concentration of 1×1011 to 1×1013 per gram. Further, methods of using the pharmaceutical are disclosed which include treatment of a gastrointestinal disorder and hypercholestermia. Also a method for modulating a host's immune response is disclosed.

Abstract: Enteral compositions containing a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis, each at a concentration equal to or greater than 1×1011 CFU per gram, are useful as adjuncts for enteral formulations and as oral nutritional supplements. The compositions can be administered before, during or at the end of an enteral formulation administration. The compositions can be administered separately or mixed with the enteral formulation. The compositions can also be employed at the end of the daily administration in order to prevent the colonization of the enteral tube by the other pathogens. The compositions can also be used as supplement to any liquid, creamy or pasty foodstuff.